Efficacy and Safety of Dupilumab in Treating Intrinsic and Extrinsic Atopic Dermatitis in Older Patients With and Without Atopic Comorbidities: A Retrospective Study
Dermatitis® · 2025
DOI: 10.1089/derm.2024.0402 ↗Kurz gefasst
Fachartikel in der Zeitschrift Dermatitis®, 2025. Verfasst von Kexin Zhao und 7 weiteren Autor:innen. Beteiligte Einrichtung: From the Institute of Dermatology and Venereology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electr…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Antibodies, Monoclonal, Humanized, Dermatologic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Background
Despite the widespread use of dupilumab in atopic dermatitis (AD) treatment, evidence supporting its use in older patients with intrinsic AD (IAD) versus those with extrinsic AD (EAD) and in those with and without atopic comorbidities remains limited.
Objective
We aimed to assess the clinical efficacy and safety of dupilumab treatment in elderly patients with IAD versus EAD and in those with and without atopic comorbidities.
Methods
We enrolled 113 older patients with severe AD who received dupilumab for 48 weeks. The inclusion criteria were age ≥60 years and Scoring Atopic Dermatitis ≥25. Patients were classified as IAD or EAD and based on the presence of atopic comorbidities. The primary outcome was a reduction in the Eczema Area and Severity Index, Numeric Rating Scale, Dermatology Life Quality Index, and Atopic Dermatitis Control Test. Secondary measures were the types and rates of adverse events.
Results
Dupilumab treatment resulted in a substantial improvement in AD symptoms, with no significant difference between patients with IAD and EAD or those with and without atopic comorbidities.
Conclusions
Dupilumab showed good efficacy and safety in improving AD symptoms in older patients, irrespective of IAD or EAD subtypes and the presence of atopic comorbidities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Institute of Dermatology and Venereology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.
- Department of Dermatology, Nanchong Central Hospital, Nanchong, China.
ORCID-Profile: Kexin Zhao, LiXia Zhang
Zitieren
APA
Zhao, K., Yang, G., Zhou, X., Yang, J., Zhao, J., Xiang, J., Chen, X., & Zhang, L. (2025). Efficacy and Safety of Dupilumab in Treating Intrinsic and Extrinsic Atopic Dermatitis in Older Patients With and Without Atopic Comorbidities: A Retrospective Study. Dermatitis®. https://doi.org/10.1089/derm.2024.0402
Vancouver
Zhao K, Yang G, Zhou X, Yang J, Zhao J, Xiang J, et al. Efficacy and Safety of Dupilumab in Treating Intrinsic and Extrinsic Atopic Dermatitis in Older Patients With and Without Atopic Comorbidities: A Retrospective Study. Dermatitis®. 2025. doi:10.1089/derm.2024.0402
BibTeX
@article{Zhao2025,
author = {Zhao, Kexin and Yang, Ge and Zhou, Xiyuan and Yang, Jianing and Zhao, Juhua and Xiang, Jing and Chen, Xuejun and Zhang, LiXia},
title = {Efficacy and Safety of Dupilumab in Treating Intrinsic and Extrinsic Atopic Dermatitis in Older Patients With and Without Atopic Comorbidities: A Retrospective Study},
journal = {Dermatitis®},
year = {2025},
doi = {10.1089/derm.2024.0402}
}
EUVIMED